Exact Mass: 400.2474
Exact Mass Matches: 400.2474
Found 112 metabolites which its exact mass value is equals to given mass value 400.2474,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Nocloprost
MG(5-iso PGF2VI/0:0/0:0)
MG(5-iso PGF2VI/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/5-iso PGF2VI/0:0)
MG(0:0/5-iso PGF2VI/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
10-O-beta-D-glucopyranosideoplopanone|oplopanone-8-O-beta-D-glucopyranoside
1-O-isopropyl-6-O-(5,9-dimethyl-2,8-decadienoyl)-beta-D-glucopyranoside|citrusoside A
1(R),4beta-dihydroxy-trans-eudesm-6-ene-1-O-beta-D-glucopyranoside
3beta,11-dihydroxy-drim-8(12)-en-11-O-beta-D-glucopyranoside|xianglinmaojueside A
3beta-[(beta-D-glucopyranosyl)oxy]eudesm-4(14)-en-11-ol
1alpha,6beta-dihydroxy-5,10-bis-epi-eudesm-4(15)-ene-6-O-beta-D-glucopyranoside|funingensin A
7-drimen-3beta-,11-diol 3-O-beta-D-glucopyranoside
3alpha-hydroxypatchoulol 3-O-beta-D-glucopyranoside
(2R*,5S*,7R*,10S*)-7-hydroperoxy-2-[(1-methyl-1-beta-D-fucopyranosyloxy)ethyl]-10-methyl-6-methylenespiro[4.5]-decane
1beta-hydroxy-3-oxo-4beta,5alpha,7alpha-H-eudesmane 11-O-alpha-L-rhamnopyranoside
2,7,11-trihydroxybisabola-1(15),9-diene 7-beta-D-fucopyranoside
2,7,10-trihydroxybisabola-1(15),11-diene 7-beta-D-fucopyranoside
(5S,6E)-5-beta-D-glucopyranosyloxy-3-hydroxy-3,7,11-trimethyldodeca-1,6,10-triene|amarantholidoside III
3beta,11-dihydroxy-drim-8(12)-en-3-O-beta-D-glucopyranoside|xianglinmaojueside B
1beta-(beta-D-glucopyranosyl)oxy-6alpha-hydroxyeudesman-4(15)-ene|1??-D-Glucopyranosyloxy-6??-hydroxyeudesman-4(15)-ene
1(R),4beta-dihydroxy-trans-eudesm-7-ene-1-O-beta-D-glucopyranoside|oplodiol 1-O-beta-D-glucopyranoside
11,14-dihydroxy-drim-8(12)-en-11-O-beta-D-glucopyranoside|xianglinmaojueside C
2-[5-[2-[2-[5-(2-hydroxybutyl)oxolan-2-yl]propanoyloxy]propyl]oxolan-2-yl]propanoic acid
2-[5-[2-[2-[5-(2-hydroxybutyl)oxolan-2-yl]propanoyloxy]propyl]oxolan-2-yl]propanoic acid [IIN-based on: CCMSLIB00000846078]
2-[5-[2-[2-[5-(2-hydroxybutyl)oxolan-2-yl]propanoyloxy]propyl]oxolan-2-yl]propanoic acid [IIN-based: Match]
2,2,2,2-(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetamide
Rapivab
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AH - Neuraminidase inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents D004791 - Enzyme Inhibitors
Amantadine sulfate
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C254 - Anti-Infective Agent > C281 - Antiviral Agent C93038 - Cation Channel Blocker
2,4-dioxo-3-pentyl-N-[3-(1-piperidinyl)propyl]-1H-quinazoline-7-carboxamide
rel-(2R,5S,7R,10S)-7-Hydroperoxy-2-[(1-methyl-1-beta-D-fucopyranosyloxy)ethyl]-10-methyl-6-methylenespiro[4.5]-decane
A natural product found in Carthamus oxyacantha.
2-(dimethylamino)-1-[(1R)-1-(hydroxymethyl)-7-methoxy-2-methyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]ethanone
2-(dimethylamino)-1-[(1S)-1-(hydroxymethyl)-7-methoxy-2-methyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]ethanone
2-[(5-hydroxy-2-isopropyl-4a,8-dimethyl-2,3,4,5,6,8a-hexahydro-1h-naphthalen-1-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
(2r)-2-[(2r,5s)-5-[(2s)-2-{[(2s)-2-[(2s,5r)-5-[(2r)-2-hydroxypropyl]oxolan-2-yl]propanoyl]oxy}butyl]oxolan-2-yl]propanoic acid
(2s,3r,4s,5r,6r)-2-({2-[(2r,5r,7r,10r)-7-hydroperoxy-10-methyl-6-methylidenespiro[4.5]decan-2-yl]propan-2-yl}oxy)-6-methyloxane-3,4,5-triol
2-(hydroxymethyl)-6-{[5-(hydroxymethyl)-1,1,4a-trimethyl-6-methylidene-hexahydro-2h-naphthalen-2-yl]oxy}oxane-3,4,5-triol
(2r,3r,4s,5r,6r)-2-{[(1s,4s,4as,8as)-4-hydroxy-4,8a-dimethyl-6-(propan-2-ylidene)-hexahydro-1h-naphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2r)-2-[(2r,5s)-5-[(2s)-2-{[(2s)-2-[(2s,5r)-5-[(2r)-2-hydroxybutyl]oxolan-2-yl]propanoyl]oxy}propyl]oxolan-2-yl]propanoic acid
(2r,3r,4s,5s,6r)-2-{[(1ar,3as,4s,7s,7as,7br)-7-hydroxy-1,1,3a,7-tetramethyl-octahydrocyclopropa[a]naphthalen-4-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2s,3r,4s,5s,6r)-2-{[(1s,4s,4as,8as)-4-hydroxy-1,4a-dimethyl-7-(propan-2-ylidene)-hexahydro-2h-naphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2s,3r,4s,5r,6r)-2-{[(1s,4s,4as,8as)-4-hydroxy-1,4a-dimethyl-7-(propan-2-ylidene)-hexahydro-2h-naphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
1β-d-glucopyranosyloxy-6α-hydroxy-eudesman-4(15)-ene
{"Ingredient_id": "HBIN002393","Ingredient_name": "1\u03b2-d-glucopyranosyloxy-6\u03b1-hydroxy-eudesman-4(15)-ene","Alias": "NA","Ingredient_formula": "C21H36O7","Ingredient_Smile": "CC(C)C1CCC2(C(CCC(=C)C2C1O)OC3C(C(C(C(O3)CO)O)O)O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "8691","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
atractyloside c
{"Ingredient_id": "HBIN017303","Ingredient_name": "atractyloside c","Alias": "NA","Ingredient_formula": "C21H36O7","Ingredient_Smile": "CC12CCC(CC1C(=C)CC(C2)O)C(C)(C)OC3C(C(C(C(O3)CO)O)O)O","Ingredient_weight": "400.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT14420","TCMID_id": "1976","TCMSP_id": "NA","TCM_ID_id": "6491","PubChem_id": "101831401","DrugBank_id": "NA"}
